Durect (Durect) 5-Year EBITDA Growth Rate : 0.40% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Durect 5-Year EBITDA Growth Rate?

Durect's EBITDA per Share for the three months ended in Dec. 2023 was $-0.03.

During the past 3 years, the average EBITDA Per Share Growth Rate was -16.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 0.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Durect was 68.50% per year. The lowest was -118.20% per year. And the median was 5.70% per year.

Competitive Comparison of Durect's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Durect's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Durect's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Durect's 5-Year EBITDA Growth Rate falls into.

Durect 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Durect (NAS:DRRX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Durect 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Durect's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Durect (Durect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

DC8A:Germany

Address

10260 Bubb Road, Cupertino, CA, USA, 95014

Website

https://www.durect.com

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Executives

Judith J. Robertson	director	10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis	director	364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp	officer: Chief Financial Officer	C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia	director	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman	officer: Chief Medical Officer	C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice	officer: Sr. VP Operations & Corp QA	10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe	director	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg	officer: Chief Financial Officer	10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown	director, officer: President & CEO	10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105